How should I screen for, diagnose, and manage steroid‑induced hyperglycemia in a patient receiving systemic glucocorticoids at a dose of ≥10 mg prednisone‑equivalent per day?

Steroid-Induced Hyperglycemia Management

Screening and Diagnosis

For any patient receiving ≥10 mg prednisone-equivalent daily, initiate blood glucose monitoring four times daily (fasting and 2 hours after each meal) immediately upon starting steroids, as hyperglycemia develops within 48 hours in 94% of cases. 1, 2

Diagnostic Criteria

• Two random glucose readings ≥11.1 mmol/L (≥200 mg/dL) on separate occasions OR a new HbA1c ≥6.5% in the context of corticosteroid use confirms steroid-induced diabetes. 1
• Persistent hyperglycemia coinciding with glucocorticoid use is considered diagnostic without requiring additional testing. 1

Critical Monitoring Points

• The most important glucose reading is 2 hours after lunch (2-3 PM), as this captures the peak hyperglycemic effect occurring 6-9 hours after morning steroid administration. 1, 3
• Target blood glucose range: 5-10 mmol/L (90-180 mg/dL) throughout the day. 1, 4
• Never rely on fasting glucose alone—this misses 70% of the hyperglycemic effect and will lead to undertreatment. 1, 4, 3
• Expect glucose to normalize overnight even without treatment due to the diurnal pattern of steroid effects. 1, 4

---

Treatment Algorithm

For Moderate Hyperglycemia (Glucose 180-270 mg/dL)

Start NPH insulin at 0.3-0.5 units/kg/day given in the morning simultaneously with the steroid dose to match the pharmacokinetic profile of prednisone. 1

• NPH peaks 4-6 hours after administration, aligning perfectly with the peak hyperglycemic effect of morning glucocorticoids. 1
• Increase NPH by 2 units every 3 days if afternoon glucose remains >180 mg/dL. 4
• For patients with pre-existing diabetes already on insulin, increase prandial (mealtime) rapid-acting insulin by 40-60% above baseline doses. 1

For Severe Hyperglycemia (Glucose >270 mg/dL or >15 mmol/L)

Persistent glucose >15 mmol/L (270 mg/dL) warrants immediate endocrinology referral. 1

Glucose >20 mmol/L or meter reading "HI" mandates immediate hospital presentation for evaluation of hyperosmolar hyperglycemic state. 1, 3

• Admit for continuous IV insulin infusion targeting 140-180 mg/dL (7.8-10.0 mmol/L). 3
• Monitor glucose every 1-2 hours initially, then every 2-4 hours once stable. 3
• Correct electrolytes, particularly potassium (hypokalemia occurs in ~50% of severe cases). 3

For High-Dose Steroids (>40 mg prednisone daily)

Increase insulin doses by 40-60% above initial dosing, as higher steroid doses cause proportionally greater hyperglycemia. 1

• For very high doses (>80 mg prednisone equivalent), "extraordinary amounts" of prandial and correctional insulin are often needed in addition to basal insulin. 1
• Consider early endocrinology consultation for patients requiring these extreme insulin doses. 1, 3

---

Special Dosing Scenarios

Nighttime Prednisone Administration

Switch from NPH to long-acting basal insulin (glargine or detemir) given at bedtime when prednisone is taken at night, as the hyperglycemic pattern shifts to overnight and the following day. 1

Long-Acting Glucocorticoids (Dexamethasone)

Use a combination of long-acting basal insulin AND NPH, as dexamethasone affects both fasting and postprandial glucose. 1

Elderly or Renally Impaired Patients

Start at the lower end of the dosing range (0.2-0.3 units/kg/day) to minimize hypoglycemia risk. 1

---

Steroid Tapering: Critical Pitfall

Any change in steroid dosage requires immediate review and adjustment of diabetes treatment—this is the most common cause of iatrogenic hypoglycemia. 1, 3

• As steroids are tapered, reduce insulin doses proportionally by the same percentage as the steroid dose reduction. 3
• Insulin requirements can decline rapidly after steroid discontinuation. 3
• Reduce insulin by 25-50% after day 5 of steroid taper to prevent hypoglycemia. 4
• Monitor for overnight hypoglycemia, as steroids often cause glucose to normalize at night even without treatment. 1

---

Role of Oral Antidiabetic Agents

Oral agents alone are insufficient for high-dose steroid therapy and should not be relied upon as monotherapy. 1, 3

When Oral Agents May Be Added:

• Metformin may be added as adjunct therapy in patients with adequate renal and hepatic function to mitigate steroid-related metabolic effects. 1
• Sulfonylureas (e.g., gliclazide) can be considered for isolated daytime hyperglycemia, provided patients are counseled about hypoglycemia risk and have adequate renal/hepatic function. 1
• DPP-4 inhibitors or GLP-1 receptor agonists are appropriate second-line agents when there is no concurrent pancreatitis or elevated lipase. 1

---

Patient Education Requirements

Educate patients on proper glucose monitoring techniques and how to interpret results, emphasizing that afternoon readings are most important. 1

Critical Warning Signs:

• Seek immediate medical attention if glucose meter reads "HI" or glucose >20 mmol/L (360 mg/dL). 1, 4
• Ketones >2 mmol/L together with glucose >15 mmol/L signals high risk for diabetic ketoacidosis and requires urgent hospital assessment. 1
• Recognize symptoms of severe hyperglycemia: excessive thirst, frequent urination, altered mental status, profound dehydration. 4, 3

Hypoglycemia Management:

• For patients receiving insulin or sulfonylureas, provide specific guidance on recognizing hypoglycemia symptoms. 1
• Treat hypoglycemia with 15g fast-acting carbohydrate. 4
• Emphasize that insulin doses must be adjusted as steroids are tapered to prevent hypoglycemia. 1, 3

---

Common Pitfalls to Avoid

Using only sliding-scale correction insulin without scheduled basal/prandial insulin is associated with poor glycemic control and is strongly discouraged. 4, 3

Failing to monitor postprandial glucose misses the peak hyperglycemic effect and leads to undertreatment. 1, 4, 3

Not reducing insulin doses when steroids are tapered is the most common cause of iatrogenic hypoglycemia. 1, 3

Discontinuing steroids to treat hyperglycemia denies patients necessary anti-inflammatory therapy for a treatable complication—always intensify diabetes treatment instead. 3